Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (يفتح نافذة جديدة)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Source‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

مفهرسة‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (يفتح نافذة جديدة)

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion. (يفتح نافذة جديدة)

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Source‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

مفهرسة‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500 (يفتح نافذة جديدة)

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT). (يفتح نافذة جديدة)

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Source‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

مفهرسة‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691 (يفتح نافذة جديدة)

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. (يفتح نافذة جديدة)

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Source‎: Blood 2003;102(4):1529-30.

مفهرسة‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505 (يفتح نافذة جديدة)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (يفتح نافذة جديدة)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Source‎: Transfusion 2007;47(10):1830-6.

مفهرسة‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (يفتح نافذة جديدة)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (يفتح نافذة جديدة)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Source‎: Iran J Blood Cancer 2009;1(4):147-50.

مفهرسة‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (يفتح نافذة جديدة)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (يفتح نافذة جديدة)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Source‎: Int J Hematol 2012;95(1):51-6.

مفهرسة‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (يفتح نافذة جديدة)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (يفتح نافذة جديدة)

Perrine SP.

Source‎: Pediatr Ann 2008;37(5):339-46.

مفهرسة‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (يفتح نافذة جديدة)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (يفتح نافذة جديدة)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Source‎: Sci Rep. 2022;12(1):2752.

مفهرسة‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (يفتح نافذة جديدة)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (يفتح نافذة جديدة)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Source‎: Haematologica 2004;89(10):1172-8.

مفهرسة‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (يفتح نافذة جديدة)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (يفتح نافذة جديدة)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Source‎: Arch Iran Med 2009;12(3):295-7.

مفهرسة‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (يفتح نافذة جديدة)

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia. (يفتح نافذة جديدة)

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Source‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

مفهرسة‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925 (يفتح نافذة جديدة)

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin. (يفتح نافذة جديدة)

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Source‎: Pediatr Hematol Oncol 1997;14(3):285-7.

مفهرسة‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215 (يفتح نافذة جديدة)

Fetal globin gene inducers: novel agents and new potential. (يفتح نافذة جديدة)

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Source‎: Ann N Y Acad Sci 2010;1202:158-64.

مفهرسة‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788 (يفتح نافذة جديدة)